Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EBS · as of Sep 30, 2025
Ownership Breakdown
183
Institutional Holders
▲ 8 vs Q2
$352.60M
Total Inst. Value
▲ $111.68M vs Q2
51.60M
Shares Outstanding
freeFloat 94.40%
41.72M
13F Shares Held
▲ 2.01M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EBS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 4.26M | 7.87% | 7.87% | $37.60B | Nov 12, 2025 | ▼ 97.8K |
OAK HILL ADVISORS LP pharmaceutical preparations | 3.61M | 6.67% | 6.67% | $16.57B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 3.54M | 6.53% | 6.53% | $31.23B | Nov 7, 2025 | ▼ 43.5K |
STATE STREET CORP pharmaceutical preparations | 2.45M | 4.51% | 4.51% | $21.57B | Nov 14, 2025 | ▲ 705.0K |
AMERICAN CENTURY COMPANIES INC pharmaceutical preparations | 2.38M | 4.40% | 4.40% | $21.01B | Nov 12, 2025 | ▲ 90.2K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 2.14M | 3.95% | 3.95% | $18.88B | Nov 12, 2025 | ▲ 291.3K |
PALISADE CAPITAL MANAGEMENT, LP pharmaceutical preparations | 1.43M | 2.63% | 2.63% | $12.58B | Nov 14, 2025 | ▲ 326.3K |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC pharmaceutical preparations | 1.38M | 2.55% | 2.55% | $12.19B | Nov 10, 2025 | ▲ 276.6K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.28M | 2.36% | 2.36% | $11.28B | Nov 12, 2025 | ▼ 305 |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 1.18M | 2.17% | 2.17% | $10.38B | Nov 13, 2025 | ▲ 203.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+4.31M shares3
New Positions
first time holders17
Decreased
−1.51M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.81M
+4.31M / −1.51M
Net new holders
+12
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EBS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
1
Sell transactions
7.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Dayal Sujata Tyagi director | Apr 30, 2026 | Award | 25,344 | — | — | 114.3K | Form 4 ↗ |
Dayal Sujata Tyagi director | May 1, 2026 | Sale | 12,781 | $8.36 | $106.8K | 101.5K | Form 4 ↗ |
Dayal Sujata Tyagi director | May 1, 2026 | Sale | 980 | $8.94 | $8.8K | 100.6K | Form 4 ↗ |
Dayal Sujata Tyagi director | Apr 30, 2026 | Award | 11,296 | $7.99 | $90.3K | 11.3K | Form 4 ↗ |
DeGolyer Donald W director | Apr 30, 2026 | Award | 25,344 | — | — | 145.2K | Form 4 ↗ |
DeGolyer Donald W director | May 1, 2026 | Sale | 14,527 | $8.36 | $121.4K | 130.7K | Form 4 ↗ |
DeGolyer Donald W director | May 1, 2026 | Sale | 954 | $8.96 | $8.5K | 129.7K | Form 4 ↗ |
DeGolyer Donald W director | Apr 30, 2026 | Award | 11,296 | $7.99 | $90.3K | 11.3K | Form 4 ↗ |
Katkin Keith director | Apr 30, 2026 | Award | 25,344 | — | — | 111.8K | Form 4 ↗ |
Katkin Keith director | Apr 30, 2026 | Sale | 15,481 | $8.28 | $128.2K | 96.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Emergent BioSolutions Inc. (EBS) is primarily owned by institutional investors, who hold approximately 80.8% of total shares outstanding. Company insiders own approximately 5.60%, while retail and public investors account for the remaining 13.55%.
The largest institutional shareholder of Emergent BioSolutions Inc. is BLACKROCK, INC., holding approximately 4.26 million shares — equal to 7.87% of outstanding shares — as of September 30, 2025.
A total of 183 institutional investors currently hold EBS stock, with a combined institutional value of approximately $352,600,064 as of the most recent 13F filing period.
Frequently asked questions
EBS ownershipEmergent BioSolutions Inc. (EBS) is primarily owned by institutional investors, who hold approximately 80.8% of shares. The largest shareholder is BLACKROCK, INC. with a 7.87% stake. Company insiders hold 5.60%. Data sourced from SEC Form 13F as of September 30, 2025.